Last edition
News about "Thryv Therapeutics"
Thryv Therapeutics Advances THRV-1268 Programme with Phase II/III Trial and FDA Fast Track Status
Thryv Therapeutics initiates Phase II/III clinical testing and secures FDA Fast Track status for THRV-1268, advancing a potential first-in-class therapy for Long QT Syndrome.
Thryv Therapeutics | 27/04/2026 | By News Bureau
Thryv Therapeutics Initiates Wave II Phase II/III Trial for Long QT Syndrome Type 2
Thryv Therapeutics has launched the Wave II Phase II/III trial to evaluate THRV-1268, an oral SGK1 inhibitor, as a potential disease-modifying therapy for adults with Long QT Syndrome Type 2.
Thryv Therapeutics | 14/01/2026 | By News Bureau | 148
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy